Bone metastases and bone loss medical treatment in prostate cancer patients - Abstract

Prostate cancer is a malignancy in urology with the highest incidence metastasize to the bone up to 70%.

The incidence of skeletal related event (SRE) by 46.1% such as severe pain, pathologic fractures, spinal compression syndrome and hypercalcemia, with a consequence of higher inpatient care and worsen the patient's prognosis. Androgen deprivation therapy (ADT) as a metastatic prostate cancer treatment itself causes an osteopenia or osteoporosis. Bisphosphonate inhibits normal and pathologic osteoclast-mediated bone resorption by several mechanisms. Denosumab is the latest treatment option in bone metastases. Multi-study shows the efficacy of denosumab is better than zoledronic acid for SRE prevention. Adverse events between denosumab and bisphosphonate are comparable.

Written by:
Safriadi F.   Are you the author?
Department of Urology, Faculty of Medicine, Padjajaran University - Hasan Sadikin Hospital. Jl. Pasteur no 38 Bandung, Indonesia.

Reference: Acta Med Indones. 2013 Jan;45(1):76-80.


PubMed Abstract
PMID: 23585414

UroToday.com Prostate Cancer Section

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe